Moderna and Merck reported Phase 3 trial results where their mRNA vaccine combined with Keytruda cut melanoma death or recurrence risk by 42%, marking a significant milestone in personalized cancer tr
Moderna and Merck announced positive data for their combination mRNA cancer vaccine intismeran and Keytruda in melanoma patients. The companies plan to present detailed study results at an upcoming in
Moderna shares surged over 60% after its vaccine combined with Merck's Keytruda met late-stage trial goals, while Brent crude hit a three-week high amid Middle East tensions. U.S. stock futures remain
Moderna and Merck announced that a personalized mRNA vaccine combined with Keytruda successfully slowed melanoma recurrence in late-stage trials. Detailed data will be presented at an upcoming medical
Regeneron shares fell 11.8% after its experimental fianlimab-cemiplimab combination failed to meet statistical significance in a late-stage melanoma trial against Merck's Keytruda. Despite a numeric i
ChemBrief